Injecting Recombinant Adeno-Associated Vectors in a Spinal and Bulbar Muscular Atrophy Mouse Model
JoVE Encyclopedia of Experiments
Neuroscience
0 views • 2:44 min • August 7th, 2025
Loading...
Overview
This article discusses a method for treating spinal and bulbar muscular atrophy (SBMA) in mice using recombinant adeno-associated virus (AAV) vectors. The approach involves delivering therapeutic microRNA to degrade mutant androgen receptor mRNA, thereby improving neuromuscular function.
Key Study Components
Area of Science
- Neuroscience
- Gene Therapy
- Muscle Disorders
Background
- SBMA is caused by a mutation in the androgen receptor gene.
- This mutation leads to the production of toxic proteins in motor neurons.
- These proteins impair signal transmission and cause muscle weakness.
- Targeting the mutant mRNA can potentially reverse these effects.
Purpose of Study
- To develop a gene therapy approach for SBMA using AAV vectors.
- To assess the effectiveness of microRNA in degrading mutant AR mRNA.
- To evaluate improvements in neuromuscular function in treated mice.
Methods Used
- Preparation of AAV vectors containing therapeutic microRNA.
- Injection of viral vectors into the tail vein of SBMA-affected mice.
- Monitoring of motor neuron function post-treatment.
- Assessment of microRNA-mediated degradation of mutant mRNA.
Main Results
- Successful delivery of AAV vectors to motor neurons.
- Degradation of mutant AR mRNA was observed.
- Improvement in neuromuscular function in treated mice.
- Reduction in toxic protein accumulation was noted.
Conclusions
- AAV-mediated delivery of microRNA is a promising strategy for treating SBMA.
- This method may help mitigate the effects of toxic protein accumulation.
- Further studies are needed to explore long-term efficacy and safety.
Frequently Asked Questions
What is SBMA?
SBMA, or spinal and bulbar muscular atrophy, is a genetic disorder caused by mutations in the androgen receptor gene.
How does the AAV vector work?
The AAV vector delivers therapeutic microRNA that targets and degrades mutant mRNA, reducing toxic protein levels.
What are the main benefits of this treatment?
The treatment aims to improve neuromuscular function and reduce muscle weakness in affected mice.
Is this method applicable to humans?
While promising, further research is needed to determine the safety and efficacy of this approach in humans.
What are microRNAs?
MicroRNAs are small non-coding RNA molecules that regulate gene expression by targeting mRNA for degradation.
How was the injection performed?
The injection was done via the tail vein of the mouse, ensuring proper technique to minimize bleeding.
Executive Industry Relevance
This method enables targeted degradation of disease-associated mutant mRNA in motor neurons, offering a precision gene therapy approach for neuromuscular disorders. By reducing toxic protein accumulation through AAV-mediated microRNA delivery, it supports mechanistic de-risking in preclinical target validation. The approach provides a scalable platform for evaluating nucleic acid therapeutics in disease-relevant models.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of mutant androgen receptor mRNA as a therapeutic target in SBMA.
- Operational Value: Supports functional target validation through measurable reduction in toxic protein levels.
- Predictive Value: Improves confidence in target mechanism by linking mRNA degradation to phenotypic improvement.
Screening & Assay Development
- Scientific Value: Produces quantifiable microRNA-mediated mRNA degradation as a biomarker of target engagement.
- Operational Value: Establishes a reproducible AAV delivery route via tail vein injection for consistent biodistribution.
- Assay Readiness: Generates standardized biological samples for downstream functional and molecular analysis.
Translational & Preclinical Research
- Disease Relevance: Uses an SBMA mouse model that recapitulates mutant AR-driven neuromuscular pathology.
- Translational Continuity: Bridges target modulation with functional outcomes in motor neuron integrity and muscle function.
- Risk-Adjusted Advancement: Provides efficacy readouts to inform go/no-go decisions in preclinical development.
Pipeline & Workflow Integration
The method fits within the discovery-to-preclinical continuum, supporting target validation through mechanistic readouts and enabling lead identification via dose-response assessment of microRNA efficacy.
- Discovery Biology: Tests the hypothesis that mutant AR mRNA degradation reduces toxicity in motor neurons.
- Screening: Delivers AAV-microRNA constructs with titration capacity for screening therapeutic candidates.
- Analytics: Measures mRNA degradation and protein reduction as quantitative endpoints for target modulation.
- Translational Research: Links molecular target engagement to neuromuscular functional improvement.
- Enterprise Reuse: Establishes a reusable AAV delivery platform for nucleic acid therapeutics in neuromuscular disease models.
Operational & Enterprise Impact
- Scientific Value: Mechanistic de-risking of mutant AR mRNA as a druggable target in SBMA.
- Operational Value: Standardized tail vein injection protocol ensures reproducible systemic delivery.
- Strategic Value: Enables data-driven target prioritization by linking molecular efficacy to phenotypic rescue.
- Portfolio Impact: Supports risk-adjusted investment in oligonucleotide or gene therapy pipelines.
Implementation Considerations
- Requires expertise in viral vector handling and murine tail vein injection techniques.
- Dependent on access to AAV production and purification infrastructure with titer quantification.
- Necessitates standardized anesthesia and warming protocols to ensure venous access and animal welfare.
- Requires molecular analytics (qPCR, Western blot) to validate mRNA degradation and protein reduction.
- Limited by transgene expression duration and potential immune responses to AAV capsid.
Biopharma FAQs
Why is mutant AR mRNA degradation critical for target validation in SBMA?
Degradation of mutant androgen receptor mRNA directly reduces toxic protein production in motor neurons, providing a mechanistic link between target engagement and functional improvement. This supports target validation by demonstrating that lowering disease-driving mRNA alleviates pathology. It enables predictive confidence in the therapeutic hypothesis.
How does tail vein injection of AAV vectors support independent variable isolation in discovery pipelines?
Tail vein injection allows systemic delivery of AAV-microRNA constructs, enabling isolated testing of the therapeutic variable across uniform biodistribution. This controls for delivery variability and ensures consistent target tissue exposure. It supports reproducible experimental conditions essential for discovery pipeline integrity.
What quantitative dependent variable measurements enable assessment of microRNA efficacy?
Quantitative PCR measures mutant AR mRNA levels, while Western blot assesses toxic protein accumulation in spinal cord and muscle tissues. Functional readouts include grip strength and rotarod performance to evaluate neuromuscular improvement. These measurements provide dose-dependent, objective endpoints for target modulation.
Why are replication requirements important for cross-functional collaboration in AAV studies?
Replication ensures that mRNA degradation and functional recovery are consistent across animals, reducing false-positive findings. This builds confidence in data shared between discovery, toxicology, and translational teams. Standardized protocols enable reliable technology transfer and comparative analysis across sites.
What statistical analysis capabilities are required before implementing AAV-microRNA studies?
Studies require power analysis to determine group sizes based on expected mRNA reduction and functional improvement. Parametric tests (e.g., t-test, ANOVA) are used to compare treated versus control groups with significance thresholds. Normality and variance checks ensure valid interpretation of target engagement and phenotypic outcomes.
08:32
Subpial Adeno-associated Virus 9 (AAV9) Vector Delivery in Adult Mice
Related Videos
0 Views
09:00
Adeno-Associated Virus-Mediated Delivery of CRISPR for Cardiac Gene Editing in Mice
Related Videos
0 Views
08:17
Direct Intrathecal Injection of Recombinant Adeno-associated Viruses in Adult Mice
Related Videos
0 Views
05:55
Delivery of Therapeutic Agents Through Intracerebroventricular (ICV) and Intravenous (IV) Injection in Mice
Related Videos
0 Views
05:12
Subpial Gene Delivery in the Mouse Spinal Cord to Evaluate Gene Expression
Related Videos
0 Views
03:33
Intrathecal Delivery of Viruses in a Mouse Model for Treating Central Nervous System Diseases
Related Videos
0 Views
03:29
Intravenous Administration of Recombinant Adeno-Associated Virus Vectors in a Rat Model
Related Videos
0 Views
06:51
Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents
Related Videos
0 Views
08:41
Adeno-associated Virus-mediated Transgene Expression in Genetically Defined Neurons of the Spinal Cord
Related Videos
0 Views
02:39
Systemic Treatment for Postnatal, Juvenile, and Runted Adult Mice by Retrobulbar Sinus Injection
Related Videos
0 Views
Last updated: 18 July 2026